Vimarsana
Biggest News Aggregation in the World

Page 6 - Pharma Analyst News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pharma Analyst. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pharma Analyst Today - Breaking & Trending Today

Pfizer and GSK to battle for share of new RSV vaccine market: Report - Vimarsana News

Pfizer and GSK to battle for share of new RSV vaccine market: Report

US drugmaker Pfizers and British pharma major GSK are likely to face significant competition in the respiratory syncytial virus (RSV) vaccine market, according to a report on Tuesday.GSK's novel vaccine, Arexvy, approved by the US FDA in May, ...

Pfizer And GSK To Battle For Share Of New RSV Vaccine Market: Report - Vimarsana News

Pfizer And GSK To Battle For Share Of New RSV Vaccine Market: Report

New Delhi, June 13 (IANS) US drugmaker Pfizers and British pharma major GSK are likely to face significant competition in the respiratory syncytial v

Source: menafn.com
Laurus Labs further invests in gene therapy tech, increases its stake in lmmunoACT to 33.86% - Vimarsana News

Laurus Labs further invests in gene therapy tech, increases its stake in lmmunoACT to 33.86%

ImmunoACT has portfolio of Chimeric Antigen Receptor T cells (CAR-T cells) therapy assets under various development stages for the treatment of multiple auto immune diseases and oncology indications.

China to launch worlds first oral insulin for Type-2 diabetes: Report - Vimarsana News

China to launch worlds first oral insulin for Type-2 diabetes: Report

New Delhi, May 26: China is soon likely to become the world's first country with oral insulin availability, according to a report on Friday.

China to launch world's first oral insulin for Type-2 diabetes: Report - Vimarsana News

China to launch world's first oral insulin for Type-2 diabetes: Report

China is soon likely to become the world's first country with oral insulin availability, according to a report on Friday.After successfully completing Phase III trials of oral insulin, China's Hefei Tianhui Biotechnology (HTIT) submitted a ...